SG Americas Securities LLC Sells 41,428 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

SG Americas Securities LLC lessened its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 72.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 15,958 shares of the company’s stock after selling 41,428 shares during the period. SG Americas Securities LLC’s holdings in Amylyx Pharmaceuticals were worth $60,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. boosted its stake in Amylyx Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock valued at $42,000 after purchasing an additional 5,104 shares during the last quarter. Barclays PLC boosted its stake in Amylyx Pharmaceuticals by 91.1% during the 3rd quarter. Barclays PLC now owns 84,572 shares of the company’s stock valued at $274,000 after purchasing an additional 40,319 shares during the last quarter. Geode Capital Management LLC boosted its stake in Amylyx Pharmaceuticals by 17.5% during the 3rd quarter. Geode Capital Management LLC now owns 551,039 shares of the company’s stock valued at $1,786,000 after purchasing an additional 82,173 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Amylyx Pharmaceuticals by 144.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock valued at $455,000 after purchasing an additional 83,048 shares during the last quarter. Finally, FMR LLC boosted its stake in Amylyx Pharmaceuticals by 292.0% during the 3rd quarter. FMR LLC now owns 221,001 shares of the company’s stock valued at $716,000 after purchasing an additional 164,622 shares during the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Price Performance

AMLX stock opened at $3.59 on Friday. The company has a market cap of $246.09 million, a P/E ratio of -0.94 and a beta of -0.54. Amylyx Pharmaceuticals, Inc. has a 1 year low of $1.58 and a 1 year high of $19.95. The stock’s fifty day moving average price is $3.84 and its 200-day moving average price is $3.72.

Wall Street Analysts Forecast Growth

Several analysts have commented on AMLX shares. Baird R W upgraded Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Leerink Partners set a $4.00 target price on Amylyx Pharmaceuticals and gave the company a “market perform” rating in a research note on Friday, October 18th. Robert W. Baird upgraded Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their target price for the company from $3.00 to $11.00 in a research note on Monday, November 18th. Bank of America upgraded Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $4.20 to $10.00 in a research note on Wednesday, October 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research note on Thursday, December 5th. Five analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.33.

Insider Activity at Amylyx Pharmaceuticals

In related news, CEO Joshua B. Cohen sold 11,851 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $3.47, for a total transaction of $41,122.97. Following the transaction, the chief executive officer now directly owns 3,201,247 shares in the company, valued at approximately $11,108,327.09. The trade was a 0.37 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Justin B. Klee sold 7,471 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $4.04, for a total value of $30,182.84. Following the transaction, the chief executive officer now owns 3,176,788 shares in the company, valued at $12,834,223.52. This trade represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,000 shares of company stock worth $84,142. Corporate insiders own 11.70% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.